Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LILLY ZYPREXA RELAPSE PREVENTION CLAIM BEING DISCUSSED WITH FDA FOR PHASE IV; OLANZAPINE PARKINSON-LIKE SIDE EFFECTS ARE SIMILAR TO PLACEBO EXPERIENCE

Executive Summary

Lilly is pursuing an explicit maintenance claim for the anti-psychotic Zyprexa in Phase IV discussions with FDA following the approval of the drug. The company and FDA will confer on the definition and endpoints that would be required to demonstrate relapse prevention in schizophrenic populations that could lead to a maintenance indication for Zyprexa. There is a lack of consensus in the U.S. scientific community on how to define relapse prevention, Lilly says.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel